Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
Clinical trial NCT05567406 · WITHDRAWN
Trial details
- NCT number
- NCT05567406
- Sponsor
- Kadmon, a Sanofi Company
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-16
- Primary completion
- 2026-08-31
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.